Cargando…

Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab

Detalles Bibliográficos
Autores principales:	Khayat-Khoei, Mahsa, Conway, Sarah, Rubinson, Douglas A., Jarolim, Petr, Houtchens, Maria K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910800/ https://www.ncbi.nlm.nih.gov/pubmed/33638680 http://dx.doi.org/10.1007/s00415-021-10463-3

Ejemplares similares

Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations
por: Mado, Hubert, et al.
Publicado: (2021)

Ocrelizumab: SARS-CoV-2 pneumonia: 2 case reports
Publicado: (2020)

Ocrelizumab/rituximab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
por: Conte, William L
Publicado: (2020)

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
por: Katz, J.D., et al.
Publicado: (2022)

Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis
por: Gibson, Elena G, et al.
Publicado: (2021)

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
por: Landsberg, Hannah E., et al.
Publicado: (2022)

Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000
por: Vieira, João, et al.
Publicado: (2021)

Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab
por: Nytrova, Petra, et al.
Publicado: (2023)

Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
por: Thornton, Jeanine Rempe, et al.
Publicado: (2020)

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
por: Conway, Sarah, et al.
Publicado: (2023)

Acute motor axonal neuropathy associated with the Pfizer SARS-CoV-2 vaccine
por: Nicolás-Sánchez, F.J., et al.
Publicado: (2022)

Transmission Cycle of SARS-CoV and SARS-CoV-2
por: Yadav, Tushar, et al.
Publicado: (2020)

Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
por: Goyal, Rajat, et al.
Publicado: (2022)

Human Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in Children
por: Aleebrahim-Dehkordi, Elahe, et al.
Publicado: (2021)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
por: Huh, Jung Eun, et al.
Publicado: (2021)

SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge
por: Ezhilan, Madeshwari, et al.
Publicado: (2021)

A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
por: Zhou, Huan, et al.
Publicado: (2021)

Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
por: Lucchini, Matteo, et al.
Publicado: (2020)

Severe breakthrough COVID-19 after SARS-CoV-2 booster vaccination in an MS patient on ocrelizumab
por: van Kempen, Zoé L.E., et al.
Publicado: (2022)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

Persistent SARS-CoV-2 Infection in a Multiple Sclerosis Patient on Ocrelizumab: A Case Report
por: Ambadapoodi, Raghava S., et al.
Publicado: (2023)

SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development
por: de Souza Silva, Guilherme Antonio, et al.
Publicado: (2020)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
por: Abdelghany, T.M., et al.
Publicado: (2021)

Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2
por: Franquet, Tomas, et al.
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
por: Li, Meng, et al.
Publicado: (2023)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Petersen, Eskild, et al.
Publicado: (2020)

Correction to: Transmission Cycle of SARS-CoV and SARS-CoV-2
por: Yadav, Tushar, et al.
Publicado: (2020)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Amyloidogenic proteins in the SARS-CoV and SARS-CoV-2 proteomes
por: Bhardwaj, Taniya, et al.
Publicado: (2023)

Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine
por: Zappa, Martina, et al.
Publicado: (2021)

A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson
por: Patel, Rikin, et al.
Publicado: (2022)

Metataxonomic Analysis of Milk Samples From SARS-CoV-2-Positive and SARS-CoV-2-Negative Women
por: Gómez-Torres, Natalia, et al.
Publicado: (2022)

SARS-CoV-2
por: Steinbauer, M., et al.
Publicado: (2020)

Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
por: Sohpal, Vipan Kumar
Publicado: (2020)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections
por: Fani, Mona, et al.
Publicado: (2020)

The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects
por: Al-Salihi, Karima A., et al.
Publicado: (2021)

Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays
por: Moran, Angelica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ae1n5rtthgll42n6dn9681ij2b